Danaher Corporation (DHR) Shares Sold by Davis Rea Ltd.
Davis Rea Ltd. lowered its position in Danaher Corporation (NYSE:DHR) by 0.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 69,881 shares of the conglomerate’s stock after selling 234 shares during the quarter. Danaher Corporation accounts for 3.7% of Davis Rea Ltd.’s investment portfolio, making the stock its 11th biggest position. Davis Rea Ltd.’s holdings in Danaher Corporation were worth $5,907,000 at the end of the most recent reporting period.
Other institutional investors have also recently modified their holdings of the company. Peddock Capital Advisors LLC boosted its holdings in Danaher Corporation by 17.4% in the first quarter. Peddock Capital Advisors LLC now owns 1,224 shares of the conglomerate’s stock valued at $105,000 after acquiring an additional 181 shares during the last quarter. Proficio Capital Partners LLC boosted its holdings in Danaher Corporation by 92.3% in the first quarter. Proficio Capital Partners LLC now owns 1,246 shares of the conglomerate’s stock valued at $105,000 after acquiring an additional 598 shares during the last quarter. ClariVest Asset Management LLC acquired a new position in Danaher Corporation in the first quarter valued at $157,000. Cornerstone Advisors Inc. boosted its holdings in Danaher Corporation by 62.0% in the second quarter. Cornerstone Advisors Inc. now owns 2,111 shares of the conglomerate’s stock valued at $178,000 after acquiring an additional 808 shares during the last quarter. Finally, Baystate Wealth Management LLC boosted its holdings in Danaher Corporation by 11.3% in the second quarter. Baystate Wealth Management LLC now owns 2,115 shares of the conglomerate’s stock valued at $181,000 after acquiring an additional 215 shares during the last quarter. Hedge funds and other institutional investors own 75.68% of the company’s stock.
In other Danaher Corporation news, insider Thomas Patrick Joyce, Jr. sold 9,772 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $81.78, for a total transaction of $799,154.16. Following the completion of the sale, the insider now directly owns 155,520 shares in the company, valued at $12,718,425.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider William King sold 7,458 shares of the company’s stock in a transaction dated Friday, July 21st. The shares were sold at an average price of $82.97, for a total transaction of $618,790.26. Following the sale, the insider now owns 18,245 shares of the company’s stock, valued at $1,513,787.65. The disclosure for this sale can be found here. Insiders have sold 71,496 shares of company stock valued at $5,916,223 over the last 90 days. Corporate insiders own 12.20% of the company’s stock.
A number of research analysts recently weighed in on the company. BidaskClub cut Danaher Corporation from a “hold” rating to a “sell” rating in a report on Tuesday, July 25th. Zacks Investment Research cut Danaher Corporation from a “buy” rating to a “hold” rating in a report on Thursday, July 27th. Citigroup Inc. set a $96.00 target price on Danaher Corporation and gave the company a “buy” rating in a report on Friday, July 21st. Royal Bank Of Canada reiterated a “hold” rating and issued a $88.00 target price on shares of Danaher Corporation in a report on Wednesday, July 12th. Finally, Janney Montgomery Scott cut Danaher Corporation from a “buy” rating to a “neutral” rating in a report on Wednesday, June 7th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the company. The company has an average rating of “Buy” and a consensus price target of $92.72.
Shares of Danaher Corporation (NYSE DHR) opened at 88.21 on Monday. The stock’s 50 day moving average price is $82.64 and its 200-day moving average price is $84.22. Danaher Corporation has a 12 month low of $75.71 and a 12 month high of $88.48. The stock has a market capitalization of $61.28 billion, a price-to-earnings ratio of 28.16 and a beta of 1.03.
Danaher Corporation (NYSE:DHR) last issued its quarterly earnings data on Thursday, July 20th. The conglomerate reported $0.99 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.97 by $0.02. Danaher Corporation had a net margin of 12.63% and a return on equity of 11.15%. The firm had revenue of $4.51 billion during the quarter, compared to analysts’ expectations of $4.50 billion. During the same period in the prior year, the company posted $0.90 earnings per share. Danaher Corporation’s revenue for the quarter was up 6.3% on a year-over-year basis. Equities analysts forecast that Danaher Corporation will post $3.95 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, October 27th. Shareholders of record on Friday, September 29th will be issued a dividend of $0.14 per share. This represents a $0.56 dividend on an annualized basis and a yield of 0.63%. The ex-dividend date of this dividend is Thursday, September 28th. Danaher Corporation’s dividend payout ratio (DPR) is 17.83%.
TRADEMARK VIOLATION NOTICE: “Danaher Corporation (DHR) Shares Sold by Davis Rea Ltd.” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2017/09/18/danaher-corporation-dhr-shares-sold-by-davis-rea-ltd.html.
Danaher Corporation Company Profile
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Stock Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related stocks with our FREE daily email newsletter.